New combo attack shows promise against tough liver tumors
NCT ID NCT07230080
First seen Nov 17, 2025 · Last updated Jun 20, 2026 · Updated 28 times
Summary
This study looks at whether a three-step treatment—blocking the tumor's blood supply (TACE), precisely targeting it with radiation (SBRT), and then boosting the immune system with drugs—can shrink liver cancers that are too advanced for surgery. Seventeen adults with intermediate to advanced hepatocellular carcinoma received this combination. Researchers are measuring how many patients respond, how long they live, and what side effects occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Nanfang Hosptial
Guangzhou, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TACE (chemoembolization), SBRT (radiation), and targeted immunotherapy (drugs that help the immune system attack cancer)
What this could lead to
If successful, this combination could offer a new treatment option for people with liver cancer that cannot be removed by surgery, potentially shrinking tumors and extending life.
What could go wrong
This is a very small, single-center study with only 17 participants and no comparison group. The results may not apply to a broader population, and the combination therapy carries risks of side effects from chemotherapy, radiation, and immune activation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.